Powder: -20°C for 3 years | In solvent: -80°C for 1 year
MPT0G211 is a highly selective and orally active HDAC6 inhibitor (IC50=0.291 nM) that has neuroprotective effects and has shown anti-metastatic activity in human breast cancer cells. MPT0G211 has 1,000 times more affinity for HDAC6 than other HDAC subtypes. MPT0G211 can cross the blood-brain barrier and could be used to improve tau phosphorylation and cognitive deficits in Alzheimer's disease models.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 98.00 | |
5 mg | In stock | $ 247.00 | |
10 mg | In stock | $ 397.00 | |
25 mg | In stock | $ 728.00 | |
50 mg | In stock | $ 987.00 | |
100 mg | In stock | $ 1,390.00 | |
500 mg | In stock | $ 2,780.00 | |
1 mL * 10 mM (in DMSO) | In stock | $ 272.00 |
Description | MPT0G211 is a highly selective and orally active HDAC6 inhibitor (IC50=0.291 nM) that has neuroprotective effects and has shown anti-metastatic activity in human breast cancer cells. MPT0G211 has 1,000 times more affinity for HDAC6 than other HDAC subtypes. MPT0G211 can cross the blood-brain barrier and could be used to improve tau phosphorylation and cognitive deficits in Alzheimer's disease models. |
Targets&IC50 | HDAC6:0.291 μM |
In vitro |
MPT0G211 (0.1 μM; cells transfected with pCAX APP 695 and pRK5-EGFP-Tau P301L for 24 h) significantly inhibits the phosphorylation of tau Ser396[3]. MPT0G211 inhibits HDAC6/Hsp90 binding, leading to subsequent proteasomal degradation of polyubiquitinated proteins[3]. MPT0G211 significantly decreases the phosphorylation of tau through GSK3β inactivation[3]. MPT0G211 (0.1 μM; 24 hours) significantly attenuates the phosphorylation of tau at Ser396 and Ser404 in both cell lines (SH-SY5Y and Neuro-2a cells transfected for 24 h with pCAX APP 695 and pRK5-EGFP-Tau P301L)[3]. MPT0G211 inhibits the growth of MDA-MB-231 and MCF-7 cells (GI50=16.19 and 5.6 μM, respectively)[2].In AML cells, MPT0G211 potentiates the cytotoxic effects of DOXO by impairing DNA repair machinery and activating Bcl-2-associated X protein (BCL-XL)-dependent cell apoptosis[1]. |
In vivo |
MPT0G211 (50 mg/kg; oral administration; daily for 3 months) significantly ameliorates spatial memory impairment[3]. MPT0G211 (25 mg/kg; intraperitoneal injection; once daily; day 73 post-tumor injection) reduces the numbers of nodules and lung weights[2]. MPT0G211 treatment not only diminishes tau phosphorylation by inhibiting GSK3β activity but also enhances the acetylation of Hsp90. This leads to the downregulation of HDAC6/Hsp90 binding and facilitates proteasomal degradation of polyubiquitinated phosphorylated tau[3]. |
Molecular Weight | 293.32 |
Formula | C17H15N3O2 |
CAS No. | 2151853-97-1 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 90 mg/mL (306.83 mM), Sonication is recommended.
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
MPT0G211 2151853-97-1 Chromatin/Epigenetic DNA Damage/DNA Repair HDAC inhibitor inhibit